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Abstract
Introduction: The aim of this study was to evaluate the blood concentration of hepatocyte growth factor (HGF) in patients at various
stages of retinopathy. We hypothesised that the high level of HGF found in diabetic patients may be an important marker of retinopathy
progression and that HGF level may be an index of the risk of proliferative retinopathy.
Material and methods: The participants in the study were 76 patients with type 1 diabetes mellitus. Of these, 35 patients were without
retinopathy and formed Group 1. Of the remaining 41 patients with retinopathy, 20 patients had non-proliferative diabetic retinopathy
(NPDR) and formed Group 2, while 21 patients had proliferative diabetic retinopathy (PDR) and formed Group 3. We evaluated the
concentration of HGF In the peripheral blood by an enzyme-linked immunosorbent assay.
Results: Mean serum concentrations of HGF in the control group were significantly lower than in the type 1 diabetic patients. We found
a significant increase in HGF serum concentrations in diabetic patients with PDR compared with the control group. Mean serum HGF
concentrations were significantly higher in diabetic subjects with PDR than in diabetic patients without retinopathy.
Conclusion: HGF concentration is increased in patients with type 1 diabetes mellitus with proliferative retinopathy, and concentrations
increase with the progression of retinopathy, suggesting that HGF plays a role in the pathogenesis of proliferative diabetic retinopathy.
(Pol J Endocrinol 2008; 59 (1): 2–5)
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Streszczenie
Wstęp: Celem pracy była ocena stężenia wątrobowego czynnika wzrostu (HGF, hepatocyte growth factor) w surowicy krwi chorych na
cukrzycę typu 1 z różnym stopniem rozwoju retinopatii cukrzycowej oraz próba oceny, czy podwyższone stężenie HGF może być bioche-
micznym markerem oceny progresji retinopatii cukrzycowej.
Materiał i metody: Badania przeprowadzono w grupie 76 chorych na cukrzycę typu 1: 35 osób bez retinopatii — grupa 1 oraz 41 osób ze
stwierdzoną klinicznie retinopatią cukrzycową: 20 osób z retinopatią nieproliferacyjną (NPDR, non-proliferative diabetic retinopathy) —
grupa 2 oraz 21 osób z retinopatią proliferacyjną (PDR proliferative diabetic retinopathy) — grupa 3. W surowicy krwi oznaczano stężenie
HGF z zastosowaniem metody immunoenzymatycznej.
Wyniki: Stwierdzono znamienny statystycznie wzrost HGF w surowicy krwi chorych z retinopatią proliferacyjną w porównianiu z grupą
kontrolną oraz chorymi na cukrzycę bez objawów retinopatii.
Wnioski: U chorych na cukrzycę typu 1 powikłaną rozwojem proliferacyjnej retinopatii cukrzycowej wzrasta stężenie HGF w surowicy
krwi. Stężenie HGF wzrasta wraz z progresją retinopatii, sugerując udział HGF w jej patogenezie. (Endokrynol Pol 2008; 59 (1): 2–5)
Słowa kluczowe: wątrobowy czynnik wzrostu; cukrzyca typu 1, retinopatia cukrzycowa
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Introduction
Type 1 diabetes mellitus accounts for only 5–10% of all
cases of diabetes but represents an important health pro-
blem, since this disorder begins early in life and leads to
long-term complications. Diabetic retinopathy is a micro-
vascular complication of diabetes and is closely correlated
with chronic long-standing hyperglycaemia [1]. The other
pathogenetic risk factors for microvascular damage in
diabetes are polyol accumulation, free radical damage
and non-enzymatic glycation of several proteins [2, 3].
Medical treatment of diabetic microangiopathy is ba-
sed on control of glycaemia, lipaemia and blood pressure
using glytazones, ACE-inhibitors, angiotensin II receptor
antagonists and statins. New knowledge of the pathoge-
nesis of microangiopathy suggests potential drugs for its
therapy (ruboxistaurin, AGE-inhibitors, angiopoietin-1 and
anti- vascular endothelial growth factor [4, 5].
Diabetes mellitus leads to endothelium dysfunction
and an accelerated progression of atherosclerosis. Dia-
betic retinal neovascularisation is considered to be
a consequence of retinal ischaemia caused by capillary
occlusion. Capillary occlusion is the result of microva-
scular thrombi in which erythrocytes, platelets and leu-
cocytes may each play a role. An ischaemic retina acts
as a source of production of upregulated growth fac-
tor, particularly vascular endothelial growth factor
(VEGF) and fibroblast growth factors, thereby inducing
new vessel formation in the surrounding tissue [6].
Numerous angiogenic factors have been reported to be
involved in development of proliferative diabetic reti-
nopathy (PDR), including insulin-like growth factors,
transforming growth factor-b, fibroblast growth factor,
tumour necrosis factor and VEGF, as well as hepatocy-
te growth factor (HGF) [7–10].
Hepatocyte growth factor is produced mainly by
the liver, but this immunoreactive peptide can be fo-
und in many tissues, including the kidney and lung, in
the endothelial cells and the vascular smooth muscle
cells [11, 12]. Recent studies have demonstrated that se-
rum levels of HGF are powerful in inducing angiogene-
sis [13]. Thus it is possible that HGF plays a role in retinal
neovascularisation in association with other factors.
The aim of this study was to evaluate the blood con-
centration of HGF in patients with different stage of
retinopathy. We hypothesised that the high level of
HGF found in diabetic patients may be an important
marker of retinopathy progression and that HGF level
may be an index of the risk of proliferative retinopathy.
Material and methods
A total of 76 type 1 diabetic patients (male/female
30/46) aged 20 to 65 years (mean ± SD 40.7 ± 11.58) who
had been treated for diabetes for more than 10 years were
recruited to the study. After ophthalmological examina-
tion the patients were divided into three groups:
— group 1 consisted of 35 patients aged 20 to 57 years
(mean age ± SD 38.94 ± 12.06 years) without diabe-
tic retinopathy; the mean duration of diabetes was
17.66 ± 12.2 years and haemoglobin A1C was 6.4%
± 1.3%;
— group 2 consisted of 20 patients aged from 28 to 62
years (mean age ± SD 42.17 ± 11.26) with non-pro-
liferative diabetic retinopathy (NPDR); the mean
duration of diabetes was 19.37 ± 12.05 years haemo-
globin A1C was 6.9% ± 0.9%;
— group 3 consisted of 21 patients aged from 27 to 65
years (mean age ± SD 43.57 ± 10.8) with PDR; the
mean duration of diabetes was 24.37 ± 8.05 years
and haemoglobin A1C was 6.7% ± 1.3%.
There was no significant difference between the stu-
died groups in systolic and diastolic blood pressure and
in the frequency of antihypertensive drug use.
The eye examination, performed by a specialised
ophthalmologist, included visual acuity, biomicrosco-
py and ophthalmoscopy, using a 90-diopter lens or di-
rect ophthalmoscopy after pupil dilatation, photogra-
phy or fluorescein angiography of the retina.
Exclusion criteria were duration of diabetes less than
ten years, other than diabetes endocrine disease, hepa-
titis and rheumatological or neoplastic diseases. The
control group consisted of 35 non-diabetic age-matched
healthy volunteers aged from 30 to 60 years mean age ±
± SD 40.3 ± 9.88 years.
Blood was collected after an overnight fast, and se-
rum was obtained by centrifugation and then stored at
–70°C. The concentration of HGF in the serum samples
was measured by an enzyme-linked immunosorbent
assay (ELISA) for human HGF (R&D Systems), accor-
ding to the manufacturer’s standard protocol. Intra-as-
say and inter-assay variations were 2.9% and 2.6%, re-
spectively. The statistical analysis was carried out using
the “Statistical 5.0 Pl” programme with Student’s t test
for normal distribution of the results in the study gro-
ups or Mann-Whitney’s U test in other than normal di-
stribution, assuming the levels p < 0.05 as statistically
significant.
All subjects had given their formal consent before
participating in the study, and the research followed
the tenets of the Declaration of Helsinki.
Results
The results of study are presented in Tables I and II.
Mean serum concentrations of HGF in the control group
were significantly lower than in the type 1 diabetic pa-
tients (930.5 ± 285.8 vs. 1098.2 ± 273.7 pg/ml, p < 0.05)
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(Tab. I). No significant difference was found between se-
rum HGF concentrations in the control patients and  in
the diabetic patients without retinopathy and with pre-
sence of NPDR. We found a significant increase
in HGF serum concentrations in diabetic patients
with PDR (Group 3) compared with the control group
1409.3 ± 309.2 vs. 930.5 ± 285.8 pg/ml, p < 0.005)
(Tab. II). The mean serum HGF concentration was signifi-
cantly higher in diabetic subjects with PDR than in diabetic
patients without retinopathy (1409.3 ± 309.2 vs. 906.5 ±
± 174.7 pg/ml, p < 0.05) and diabetic patients with NPDR
(962.9 ± 210.9 vs. 1409.3 ± 309.2 pg/ml, p < 0.05) (Tab. II).
Discussion
In the retinas of patients with diabetes the earliest pa-
thophysiological changes include selective loss of capil-
lary pericytes, proliferation of endothelial cells, impair-
ment of retinal autoregulation and, in consequence,
failure of the capillary circulation. These changes lead
to increased retinal vascular permeability and chronic
retinal hypoxia, resulting in retinal neovascularisation.
These processes are mediated by various growth fac-
tors, such as hepatocyte growth factor. Blood and in-
traocular concentrations of VEGF have been studied
[14–16] and the authors concerned have reported incre-
ased concentrations of VEGR in PDR patients [14, 15].
This growth factor has a potent angiogenic action and
it is expected that increased VEGF would be involved
in neovascularisation in PDR. HGF also has an angio-
genic action as well as an endothelium-specific growth
action and the effect of HGF is reported to be stronger
than that of VEGF [17]. This finding supports the idea
that HGF, together with VEGF, may be involved in reti-
nal neovascularisation in PDR. HGF, which is identical
to scatter factor [18, 19], is a disulfide-linked heterodi-
meric molecule composed of a 69-kDa kringle-conta-
ining a-chain and a 34-kDa b-chain [20, 21]. Although
HGF has been well characterised as a hepatotrophic [22,
23] and renotrophic factor [24, 25] in liver and kidney
regeneration, the presence of the local HGF system
(HGF and its receptor c-met) has been demonstrated in
both endothelial cells and vascular smooth muscle cells
in vivo and in vitro [26].
Shinoda et al. studied concentrations of HGF and
VEGF in the peripheral blood and aqueous fluid of pa-
tients with diabetic retinopathy [16]. In contrast to our
results these authors found no significant difference in
serum concentrations of the growth factors studied be-
tween non-diabetic patients, diabetic patients without
retinopathy and diabetic patients with different stages
of retinopathy (NPDR and PDR).On the other hand,
the aqueous HGF level increased with the stage of reti-
nopathy. The aqueous VEGF level in PDR was signifi-
cantly higher than in non-diabetic patients and diabe-
tic patients without retinopathy. Nishimura et al. re-
ported that the mean HGF concentration in the vitre-
ous is higher in diabetic subjects with PDR than in either
non-diabetic subjects or diabetic subjects without PDR.
The vitreous HGF concentration in diabetic subjects
without PDR was almost the same as in the non-diabe-
tic control subjects and was much lower than in the PDR
Table II. Blood concentration of hepatocyte growth factor (HGF) in type 1 diabetes at different stages in the development of
diabetic retinopathy
Tabela II. Stężenie wątrobowego czynnika wzrostu (HGF) w surowicy krwi chorych na cukrzycę typu 1 z różnym stopniem
rozwoju retinopatii cukrzycowej
Means and standard deviation p (Mann-Whitney U)
Group 1 (n=35) Group 2 (n=20) Group 3 (n=21) Control (n=35)
HGF pg/ml 906.5 ± 174.7 962.9 ± 210.9 1409.3 ± 309.2 930.5 ± 285.8 p=0.09 (NS)
p* = 0.197 (NS)
p** < 0.005
p*** < 0.05
p**** < 0.05
Group 1 — patients without diabetic retinopathy; Group 2 — patients with non-preproliferative diabetic retinopathy (NPDR); Group 3 — patients with
proliferative diabetic retinopathy (PDR); p — control group vs. Group 1; p* — control group vs. Group 2; p**— control group vs. Group 3; p***— group 1
vs. Group 3; p**** — group 2 vs. Group 3
Table I. Blood concentration of hepatocyte growth factor
(HGF) in type 1 diabetes: patients and control group
Tabela I. Stężenie wątrobowego czynnika wzrostu (HGF)
w surowicy krwi chorych na cukrzyce typu 1 oraz w grupie
kontrolnej
                       Means and standard  p (Mann-
deviation -Whitney U)
Diabetes type 1 Control
(n=76) (n=35)
HGFpg/ml 1098.2 ± 273.7 930.5 ± 285.8 p < 0.05
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subjects [14]. In the other study Nishimura et al. [15]
found a high concentration of HGF not only in the ori-
ginal vitreous but also in the artificial vitreous after vi-
trectomy of patients with PDR. The authors concluded
that vitreous HGF plays a role not only in the occurren-
ce of PDR but also in its recurrence after vitrectomy. In
a previous study Nishimura et al. reported that serum
concentrations of HGF were lower in diabetic patients
without retinopathy. The mean serum HGF concentra-
tion did not differ between diabetic patients with and
those without the presence of NPDR and pre-PDR.
Serum concentrations of HGF increased in patients with
PDR who had not undergone photocoagulation, which
is consistent with our results [27].
Canton et al. [28] found a significantly elevated intra-
vitreous concentration of HGF in diabetic patients with
PDR compared with non-diabetic patients. Intravitreous
HGF concentrations were strikingly higher than serum
HGF concentrations both in diabetic patients and in the
control group. No correlation was found between se-
rum and vitreous levels of HGF and the authors con-
cluded that intraocular synthesis of HGF in PDR rather
than serum diffusion is directly involved in the neova-
scularisation process [28]. These findings suggest that
HGF could play a role in neovascularisation in PDR.
Conclusion
Concentrations of hepatocyte growth factor are incre-
ased in patients with type 1 diabetes mellitus with pro-
liferative retinopathy, and the concentration increases
with the progression of the retinopathy. This suggests
that hepatocyte growth factor plays a role in the patho-
genesis of diabetic proliferative retinopathy.
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